Red pee, or what appears to be blood in urine, has many causes. Here's how to tell if it's harmless or a sign of a more ...

On November 3, the 12th Annual Tencent WE Summit took place at the Chengdu Science Fiction Museum. Five world-renowned ...

Cancer is the second leading ... Trust to conduct research into the evolution of kidney cancer tumours and how there are difference in its microscopic structure. The aim is to help doctors provide ...

The blood level of glucose was normal, as were the results of tests of kidney ... cancer cells to escape host immunity. 4 A weakened immune system may be especially important in the development ...

Examples of functional GI diseases include irritable bowel syndrome (IBS) and acid reflux, while examples of structural GI diseases include hemorrhoids, diverticulosis, and colon cancer ... an abscess ...

The tool was then trained further on 60,000 whole-slide images of tissues including lung, breast, prostate, colorectal, stomach, esophageal, kidney ... of Defense Peer Reviewed Cancer Research Program ...

The NHS has issued a warning as a common bedtime symptom could actually signal kidney cancer. Also known as renal cancer, kidney cancer is the sixth most common cancer in the UK. According to ...

Opens in a new tab or window LOUISVILLE, Ky. -- Minimally invasive ablative therapy for early kidney cancer had an increased risk of local and metastatic recurrence, which is associated with ...

Opens in a new tab or window LOUISVILLE, Ky. -- A CD70-targeted CAR T-cell therapy for advanced kidney cancer continued to show durable activity in treatment-refractory patients, according to ...

"I find the development of the kidney to be a really beautiful process ... a Bioengineering Ph.D. graduate -; carefully analyzed microscopic images of developing animal kidneys at different ...

An expert explained the advantages and disadvantages of radiation as a treatment for patients with renal cell carcinoma, a type of kidney cancer. Discussions with the care team around radiation as a ...

With new data out on Arcus Biosciences’ experimental HIF-2a inhibitor, one group of analysts figures the company could give Merck’s Welireg a run for its money in kidney cancer. In the phase 1 ...